Biopolym. Cell. 2012; 28(2):121-128.
http://dx.doi.org/10.7124/bc.00003D
Structure and Function of Biopolymers
Study of molecular mechanisms of proapoptotic action of novel heterocyclic 4-thiazolidone derivatives
1Panchuk R. R., 2Chumak V. V., 2Fil' M. R., 3Havrylyuk D. Ya., 3Zimenkovsky B. S., 3Lesyk R. B., 1, 2Stoika R. S.
  1. Institute of Cell Biology, NAS of Ukraine
    14/16, Drahomanov Str., Lviv, Ukraine, 79005
  2. Ivan Franko National University of L'viv
    4, Hrushevskoho Str., Lviv, Ukraine, 79005
  3. Danylo Halytsky Lviv National Medical University
    69, Pekarska Str., Lviv, Ukraine, 79010

Abstract

Aim. Mechanisms of induction of apoptosis signaling pathways in mammalian tumor cells treated by novel heterocyclic 4-thiazolidones with different side groups were studied. Methods. Annexin V/propidium iodide and DAPI (4',6-diamidino-2-phenylindole) staining of cells, Western-blot analysis of specific proteins. Results. 4-Thiazolidone derivatives of various structure possess similar cytotoxic activity in vitro (IC50 = 5 µM), and induce apoptosis in both leukemia (Jurkat, CCRF-CEM) and carcinoma (MCF-7, MDA-MD-231) cells. Western-blot analysis of the expression of several proteins of apoptosis signaling showed that the structure of lateral groups of 4-thiazolidones may directly affect biological activity of these proteins in leukemia cells. In particular, compounds Les-3120 (pyrazoline-substituted thiazolidinone) and Les-3166 (thiazolidinone-benzothiazole conjugate) induced receptor-mediated apoptosis in Jurkat T-leukemia cells. 4-Iminothiazolidinone Les-3372 caused mitochondrial type apoptosis, mediated by AIF protein. Conclusions. Structure-functional relationships between the presence of specific side groups in novel 4-thiazolidones and the signaling apoptotic pathways induced by these compounds have been established. The obtained results allow designing new, «hybrid» compounds which can simultaneously induce more than one apoptotic pathway in tumor cells.
Keywords: tumor cells, apoptosis, 4-thiazolidones, caspases, AIF, structure-functional relationships
Full text: (PDF, in English)

References

[1] Havrylyuk D., Kovach N., Zimenkovsky B., Vasylenko O., Lesyk R. Synthesis and anticancer activity of isatin-based pyrazolines and thiazolidines conjugates. Arch. Pharm. (Weinheim.) 2011 344, N 8:514–522.
[2] Havrylyuk D., Mosula L., Zimenkovsky B., Vasylenko O., Gzella A., Lesyk R. Synthesis and anticancer activity evaluation of 4thiazolidinones containing benzothiazole moiety. Eur. J. Med. Chem 2010 45, N 11:5012–
[3] Havrylyuk D., Zimenkovsky B., Vasylenko O., Zaprutko L., Gzella A., Lesyk R. Synthesis of novel thiazolone-based compounds containing pyrazoline moiety and evaluation of their anticancer activity. Eur. J. Med. Chem 2009 44, N 4:1396–1404.
[4] Kaminskyy D., Zimenkovsky B., Lesyk R. Synthesis and in vitro anticancer activity of 2,4-azolidinedione-acetic acids derivatives. Eur. J. Med. Chem 2009 44, N 9:3627–3636.
[5] Lesyk R. B., Zimenkovsky B. S. 4-Thiazolidones: centenarian history, current status and perspectives for modern organic and medicinal chemistry. Curr. Org. Chem 2004 8, N 16:1547– 1579.
[6] Lesyk R., Kryshchyshyn A., Zimenkovsky B., Atamanyuk D., Havrylyuk D., Kaminsky D., Khyluk D., Nektegayev I., Subtel’na I., Roman O., Holota S. Anticancer potential of 4-azolidones and related heterocycles. Ann. Univ. Mariae Curie-Sklodowska. Med 2006 19, N 1:107–110.
[7] Lesyk R., Zimenkovsky B., Subtelna I., Nektegayev I., Kazmirchuk G. Synthesis and antiinflammatory activity of some 2-arylamino-2-thiazoline-4-ones. Acta Pol. Pharm 2003 60, N 6:457–466
[8] Kucukguzel S. G., Oruc E. E., Rollas S., Sahin F., Ozbek A. Synthesis, characterisation and biological activity of novel 4-thiazolidinones, 1,3,4-oxadiazoles and some related compounds. Eur. J. Med. Chem 2002 37, N 3:197–206.
[9] Peterson G. L. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal. Biochem 1977 83, N 2:346–358.
[10] Edinger A. L., Thompson C. B. Death by design: apoptosis, necrosis and autophagy. Curr. Opin. Cell Biol 2004 16, N 6:663–669.
[11] Vermes I., Haanen C., Steffens-Nakken H., Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods 1995 184, N 1:39–51.
[12] Kim R., Tanabe K., Uchida Y., Emi M., Inoue H., Toge T. Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy. Cancer Chemother. Pharmacol 2002 50, N 5:343–352.
[13] Engels I. H., Stepczynska A., Stroh C., Lauber K., Berg C., Schwenzer R., Wajant H., Janicke R. U., Porter A. G., Belka C., Gregor M., Schulze-Osthoff K., Wesselborg S. Caspase-8/ FLICE functions as an executioner caspase in anticancer drug-induced apoptosis. Oncogene 2000 19, N 40:4563–4573.
[14] Kischkel F. C., Hellbardt S., Behrmann I., Germer M., Pawlita M., Krammer P. H., Peter M. E. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 1995 14, N 22:5579–5588.
[15] Shawgo M. E., Shelton S. N., Robertson J. D. Caspase-9 activation by the apoptosome is not required for fas-mediated apoptosis in type II Jurkat cells. J. Biol. Chem 2009 284, N 48 P. 33447–33455.
[16] Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K. J., Debatin K. M., Krammer P. H., Peter M. E. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998 17, N 6:1675–1687.
[17] Kim H., Rafiuddin-Shah M., Tu H. C., Jeffers J. R., Zambetti G. P., Hsieh J. J., Cheng E. H. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat. Cell Biol 2006 8, N 12:1348–1358.
[18] Tsujimoto Y., Shimizu S. VDAC regulation by the Bcl-2 family of proteins. Cell Death Differ 2000 7, N 12:1174–1181.
[19] Li P., Nijhawan D., Budihardjo I., Srinivasula S. M., Ahmad M., Alnemeri E. S., Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates apoptotic protease cascade. Cell 1997 91, N 4:479–489.
[20] Gogvadze V., Orrenius S., Zhivotovsky B. Mitochondria as targets for cancer chemotherapy. Semin. Cancer Biol 2009 19, N 1:57–66.
[21] Vakifahmetoglu-Norberg H., Zhivotovsky B. The unpredictable caspase-2: what can it do?. Trends Cell Biol 2010 20, N 3:150–159.